Jalava Päivi, Kuopio Teijo, Huovinen Riikka, Laine Juhana, Collan Yrjö
Department of Pathology, University of Turku, Turku, Finland.
Anticancer Res. 2005 May-Jun;25(3c):2535-42.
Estrogen (ER) and progesterone (PgR) receptors are predictive and prognostic factors in breast cancer. The most suitable immunohistochemical cutpoints for dividing the tumors in hormone receptor-negatives and -positives may, however, need more consideration. We examined the association between breast cancer survival and cutpoints assessed by four different models. We looked for evidence for which patient subgroups could be handled best through applying different cutpoints.
Three hundred and twenty-four samples of invasive breast cancer were immunohistochemically stained for ER and PgR, bcl-2 and erbB2. Fractions of ER- and PgR-positive cells and also ER and PgR staining scores were assessed. The fractions of stained cells and staining scores, respectively, were determined on the whole section area, and the area of most intense staining. Candidate cutpoints, dividing the patients into good and poor prognosis groups, were tested among all patients group, N+ and N- groups, premenopausal and postmenopausal patient groups. The correlation between immunohistochemistry results of ER, PgR, bcl-2 and erbB2 as well as SMI (standardized mitotic index), patient age, tumor size and axillary lymph node status were tested.
The ER score was correlated with age, SMI and bcl-2 positivity. The PgR score was correlated with erbB2 and bcl-2. Lobular carcinomas had higher staining scores of ER and PgR than ductal carcinomas.
In this material, ER was correlated with factors reflecting the differentiation of the tumor. On the basis of the ER and PgR immunohistochemistry cutpoint analysis, we found that the optimal cutpoints in different patient groups may not be the same.
雌激素(ER)和孕激素(PgR)受体是乳腺癌的预测和预后因素。然而,对于将肿瘤分为激素受体阴性和阳性的最合适免疫组化切点可能需要更多考虑。我们研究了乳腺癌生存率与四种不同模型评估的切点之间的关联。我们寻找证据,以确定哪些患者亚组通过应用不同切点可以得到最佳处理。
对324例浸润性乳腺癌样本进行ER、PgR、bcl-2和erbB2免疫组化染色。评估ER和PgR阳性细胞分数以及ER和PgR染色评分。分别在整个切片区域和染色最强烈区域测定染色细胞分数和染色评分。在所有患者组、N+和N-组、绝经前和绝经后患者组中测试将患者分为预后良好和不良组的候选切点。测试ER、PgR、bcl-2和erbB2免疫组化结果以及标准化有丝分裂指数(SMI)、患者年龄、肿瘤大小和腋窝淋巴结状态之间的相关性。
ER评分与年龄、SMI和bcl-2阳性相关。PgR评分与erbB2和bcl-2相关。小叶癌的ER和PgR染色评分高于导管癌。
在本研究材料中,ER与反映肿瘤分化的因素相关。基于ER和PgR免疫组化切点分析,我们发现不同患者组的最佳切点可能不同。